HARVARD BIOTECH INCUBATOR

The Harvard Biotech Incubator (HBI) focuses on developing and applying marketable skills and strategies to prepare students and postdocs for careers in biotechnology. Our team collaborates with industry leaders to bring a novel idea or technology from the laboratory bench to the market.  

 
 

ADVISORS

csm_481_1468382849_624cc48d6a.jpg

Carl Novina, MD, PhD

Associate Professor, Dana-Farber Cancer Institute & Harvard Medical School
Associate Member, Broad Institute of Harvard and MIT 

 

 
2ec264f.jpg

Fred Mermelstein, PhD

Entrepreneur in Residence at Dana Farber Cancer Institute

Chairman of the Board Pear Tree Pharmaceuticals, Inc.
Vice-Chairman of the Board Linus Oncology, Inc. 
Member of the Boston Harbor Angels                                                           Former CEO/President of Javelin Pharmaceuticals, Inc.

 

 

CURRENT PROJECTS

Epigenetic Reprogramming Platform Technology 

Working with a modified Cas9 technology developed in Dr. Novina's laboratory, HBI members performed due diligence on genetic targets and indications and presented their findings. Product profile sheets were produced for the leading indications, and this fall we will begin drafting a business plan for this novel epigenetic engineering platform. 

 

Cellular Immunotherapy for Treating Cancer and Autoimmune Diseases

.... NEW PROJECT FOR FALL 2016

 

IMG_2606.jpg

PAST PROJECTS

Enteromics, Inc. 

 Enteromics is a newly formed company that has acquired the worldwide intellectual property rights for the use of naturally occurring bacteria molecularly engineered for detection and treatment of diseases of the gastrointestinal (GI) tract. Enteromics’ strategy is to modify bacterial membranes with specific proteins that bind specifically to diseased tissues sparing normal healthy tissue. Enteromics’ bacteria are further modified to carry a wide range of payloads such as light-emitting molecules for direct visualization; non-invasive imaging dyes for virtual imaging including PET, CT and MRI scanning; molecules that modulate inflammatory states; and chemotherapeutic compounds. Enteromics’ platform technology enables detection, imaging and treatment of a wide range of conditions caused by inflammation, erosion, abnormal cell growth, and cancer.

 

LEADERSHIP

 

For more information please contact: hbincubator@gmail.com

NEXT MEETING: HBI Info Session 

Thursday, September 29th @ 1pm TMEC 306  RSVP HERE